United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tipranavir - oral solution - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

nova laboratories ltd - mercaptopurine - oral suspension - 20mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - prednisolone - oral solution - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - desloratadine - oral solution - 500microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - desloratadine - oral solution - 500microgram/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - ranitidine hydrochloride - oral solution - 15mg/1ml